Hemodynamic and cardiac effects of the selective T-type and L-type calcium channel blocking agent midefradil in patients with varying degrees of left ventricular systolic dysfunction

Journal of the American College of Cardiology

Volumn 28, Issue 4, 1996, Pages 972-979

  Rousseau, Michel F ^a   Hayashida, Wataru ^a   Van Eyll, Christian ^a   Hess, Otto M ^b   Benedict, Claude R ^c   Chapelle, Frédéric ^a   Kobrin, Isaac ^a   Pouleur, Hubert ^a  

^a UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^c UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM CHANNEL; CALCIUM CHANNEL BLOCKING AGENT; DIHYDROPYRIDINE DERIVATIVE; MIBEFRADIL; NIFEDIPINE;

ADULT; AGED; ARTICLE; CARDIOVASCULAR RESPONSE; CATECHOLAMINE BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFECT; DRUG SELECTIVITY; FEMALE; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FAILURE; HEMODYNAMIC PARAMETERS; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; ISCHEMIC HEART DISEASE; MALE; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PLASMA RENIN ACTIVITY; PRIORITY JOURNAL; SYSTOLE;

EID: 0030273422     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(96)00261-6     Document Type: Article

References (26)

1. Ruzicka M, Leenen FHH. Relevance of intermittent increases in sympathetic activity for adverse outcome on short-acting calcium antagonists. In: Laragh JH, Brenner BM, editors. Hypertension: Pathophysiology, Diagnosis and Management. New York: Raven Press, 1995:2815-25.
2. Furberg CD, Psaty BM, Meyer JV. Nifedipine: dose-related increase in mortality in patients with coronary heart disease. Circulation 1995;92:1326-31.
3. Packer M. Pathophysiological mechanisms underlying the adverse effects of calcium channel-blocking drugs in patients with chronic heart failure. Circulation. 80:1989;59-67.
4. Pouleur H. Calcium entry blockers in congestive heart failure and in asymptomatic left ventricular dysfunction. In: Barnett D, Pouleur H, Francis G, editors. Heart Failure. New York: Marcel Dekker, 1993:287-301.
5. Aursnes I, Litleskare I, Froyland H, Abdelnoor M. Association between various drugs used for hypertension and risk of acute myocardial infarction. Blood Pressure 1995;4:157-63.
6. Psaty BM, Heckbert SR, Koepsell TD, et al. The risk of myocardial infarction associated with antihypertensive drug therapies. JAMA 1995;274:620-5.
7. Pahor M, Guralnik JM, Corti MC, Foley DJ, Carbonin P, Havlik RJ Long-term survival and use of antihypertensive medications in older persons. J Am Geriatr Soc. 43:1995;1-7.
8. ++ channels. J Pharmacol Exp Ther 1994;271:1483-8.
9. 2+ channels by Ro 40-5967. Circ Res 1994;75:144-8.
10. Clozel JP, Osterrieder W, Kleinbloesem CHet al. Ro 40-5967: a new nondihydropyridine calcium antagonist. Cardiovasc Drug Rev. 9:1991;4-17.
11. Portegies MCM, Schmitt R, Kraiij CJ, et al. Lack of negative inotropic effects of the new calcium antagonist Ro 40-5967 in patients with stable angina pectoris. J Cardiovasc Pharmacol 1991;18:746-51.
12. Rousseau MF, Gurné O, van Eyll C, Benedict CR, Pouleur H. Effects of benazeprilat on left ventricular systolic and diastolic function and neurohumoral status in patients with ischemic heart disease. Circulation 1990;81 Suppl III:III-123-9.
13. Mirsky I. Elastic properties of the myocardium: a quantitative approach with physiological and clinical applications. In: Berne RM, Sperelakis N, editors. Handbook of Physiology, Section 2: The Cardiovascular System. Baltimore: Williams & Wilkins, 1979:497-531.
14. van Eyll C, Pouleur H, Charlier AA, Brasseur LA, Gurné O, Rousseau MF. Interest of quantitative diastolic regional wall motion analysis in ischemic heart disease. In: Computers in Cardiology. Salt Lake City: IEEE Computer Society, 1984:219-22.
15. Braunwald E, Ross J Jr, Sonnenblick EH. Methods for assessing cardiac contractility. In: Braunwald E, Ross J Jr, Sonnenblick EH, editors. Mechanisms of Contraction of the Normal and Failing Heart. Boston: Little Brown, 1976:130-65.
16. Hussain MN, Benedict CR. Radioenzymatic microassay for simultaneous estimations of dopamine, norepinephrine, and epinephrine in plasma, urine and tissues. Clin Chem 1985;31:1861-4.
17. Sealy J, Laragh JH. How to do plasma renin assay. In: Laragh JH, editor. Topics in Hypertension. New York, York Medical Books, 1980:244-56.
18. Muntinga HJ, van der Vring JAFM, Niemeyer MG, et al. Effect of mibefradil on left ventricular diastolic function in patients with congestive heart failure. J Cardiovasc Pharmacol 1996;27:652-6.
19. Bean BP. Classes of calcium channels in vertebrate cells. Annu Rev Physiol 1989;51:367-84.
20. Hermsmeyer K. Differences of calcium channels in vascular muscle in hypertension. Am J Hypertens 1991;4:412-5.
21. Rousseau MF, Vincent MF, Van Hoof F, Van den Berghe G, Charlier AA, Pouleur H. Effects of nicardipine and nisoldipine on myocardial metabolism, coronary blood flow and oxygen supply in angina pectoris. Am J Cardiol 1984;54:1189-94.
22. Packer M, Lee WH, Medina N, Yushak M, Berstein JL, Kessler PD. Prognostic importance of the immediate hemodynamic response to nifedipine in patients with severe left ventricular dysfunction. J Am Coll Cardiol 1987;10:1303-11.
23. Feldman MD, Copelas L, Gwathmey JK, Phillips P, Warren SE, Schoen FJ. Deficient production of cyclic AMP: pharmacologic evidence of an important cause of contractile dysfunction in patients with end-stage heart failure. Circulation 1987;75:331-9.
24. Packer M, Kessler PD, Lee WH Calcium-channel blockade in the management of severe congestive heart failure: a bridge too far. Circulation. 75:1987;56-64.
25. Braun S, van der Wall EE, Emanuelsson H, Kobrin I, on behalf of the Mibefradil International Study Group. Effects of a new calcium antagonist, mibefradil (Ro 40-5967), on silent ischemia in patients with stable chronic angina pectoris: a multicenter placebo-controlled study. J Am Coll Cardiol 1996;27:317-22.
26. Pressler ML, Carson PE, Miller ABet al. for the PRAISE Investigators. Safety of amlodipine in severe heart failure: reduction of sudden death in non-ischemic heart disease [abstract]. J Am Coll Cardiol. 27(Suppl A):1996;281A.